APOE and amyloidosis: In addition, the PrecivityADTM test for plasma LC-MS/MS assays of Aβ quantification and qualitative APOE isoform-specific prototyping was completed in the first phase of the Plasma test for Amyloid Risk Screening study for clinical use to evaluate individuals experiencing early cognitive impairment [74].